We are looking for a hands-on Senior Medical Director (m/f/x) to support our global Phase 3 registrational study in progressive Multiple Sclerosis. In this role, you will provide medical and clinical leadership across study planning and execution, define key medical strategies, and drive protocol development. You will serve as the clinical representative in regulatory interactions, oversee ongoing safety monitoring, and collaborate closely with external medical experts to ensure scientific excellence and successful study delivery.

• Clinical Strategy & Leadership: Define and execute the medical strategy for Phase 3 clinical trials, including protocol design, study execution, and data analysis.
• Regulatory & Safety Oversight: Provide medical leadership during regulatory interactions (e.g., FDA/EMA) and oversee patient safety, including review of serious adverse events (SAEs).
• Scientific Expertise & External Engagement: Act as the primary medical expert, collaborating with the medical advisory board and investigators, and representing the study at scientific meetings.
• Cross-Functional Collaboration: Work closely with Clinical Operations, Regulatory Affairs, Medical Affairs, and Commercial teams to align on study milestones, data readouts, and launch preparation.
• Data Interpretation: Analyze and interpret Phase 3 data to support regulatory submissions, reimbursement activities, and scientific publications.

We offer

• A permanent position in an international and highly motivated team.
• A dynamic, flexible and innovative working environment.
• Participation in our company’s success through our stock option program.
• Competitive compensation, comprehensive benefits and opportunities for professional growth.
• Further benefits that promote our employee’s health and well-being: Wellpass, OpenUp, and more.

Join us and be part of a company where your work directly contributes to our mission of improving
patient care through groundbreaking research. Immunic AG offers a stimulating work environment where
innovation and collaboration are valued.

Immunic Therapeutics is a dynamic biotechnology company with a pipeline of selective, orally available immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Currently, three small molecule product candidates are in various stages of clinical development. For more information, please visit: www.imux.com .